MSCs are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Mesenchymal Stem Cells, Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform
LONDON, UK and BOCA RATON, FL, — INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the world’s first stem cell register and is now driving forward cell therapy advancements, announced the signing of an amended and restated Material Transfer and License Agreement. This expanded collaboration secures the long-term provision of high-quality umbilical cord tissue to power INmune Bio’s CORDStrom™ platform, the industry’s most advanced Mesenchymal Stromal Cell (MSC) technology designed to deliver consistent, scalable, and “off-the-shelf” cellular therapies which are suitable for supply in UK, EU and US, as well as other global regions. [Read more…]
Factor Bioscience to Reveal Two Novel iPSC-derived MSC (iMSC) Programs at ASGCT 2026
- Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs
- Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors (FACT-112), as well as recent advances in Factor’s RNA-based cell reprogramming technologies
- Factor to reveal two novel iPSC-derived mesenchymal stem cell (iMSC) programs: Hypoimmune iMSCs for muscular dystrophy and HTRA1-expressing iMSCs for neurodegenerative disorders
RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China
Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillment
FREDERICK, MD., April 8, 2026 — RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered bioprocess media, and advanced therapy manufacturing solutions for hMSCs and exosomes, today announced an exclusive distributor partnership with MineBio Life Sciences Limited (MineBio), a trusted partner to China’s biopharmaceutical and advanced therapy community. Under the agreement, MineBio will distribute RoosterBio’s full platform of research-grade and CliniControlTM cGMP-grade MSC and exosome bioprocessing media throughout China. Critically, MineBio has already secured import approval for RoosterBio’s research use only and cGMP CliniControlTM MSC and exosome bioprocessing media platform, enabling orders to be fulfilled without delay. [Read more…]
MSCs: A Multi-Version Medicinal Technology System, Part I
The Most Interesting Things Take Time
The world’s first approved product from monoclonal antibody technology was Muromonab-CD3 (Orthoclone OKT3), launched in 1986. It’s a prime example of “mAb version 1.0,” unleashed before a wave of newer, more manufacturable and better engineered products would begin to enter the market in the late-90s. Later molecular and process iterations based on “mAb 1.0” would take several decades to finally ramify into diverse platforms such as CAR-T, Bi-specific T-cell engagers (BiTEs), diagnostics, and biosensors. As a cellular technology platform, mesenchymal stem/stromal cells (MSCs) are proceeding with a story of convergent evolution. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 59
- Next Page »